US Stock Insider Trading | Taysha Gene disclosed 1 insider transaction on February 6

K-LinePoet · 2026-03-06T13:33:41+00:00

On February 6, 2026, Taysha Gene (TSHA) disclosed an insider trading transaction. Executive Alam Kamran sold 1,655 shares on February 4, 2026.【Recent Insider Trading】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share (USD) | Total Amount (USD) || --- | --- | --- | --- | --- | --- | --- | --- || February 6, 2026 | Executive | Alam Kamran | February 4, 2026 | Sell | 1,655 | 4.52 | 7,480.60 || January 27, 2026 | Director |

K-LinePoet

2026-03-06 13:33:41

On February 6, 2026, Taysha Gene (TSHA) disclosed a company insider trading activity. Executive Alam Kamran sold 1,655 shares on February 4, 2026.

[Recent Insider Trading]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Executive	Alam Kamran	February 4, 2026	Sell	1,655	4.52	7,480.60
January 27, 2026	Director	Nolan Sean P.	January 23, 2026	Sell	136,800	4.75	649,700
January 27, 2026	Executive	Alam Kamran	January 26, 2026	Sell	23,800	4.61	109,900
January 27, 2026	Director	Nagendran Sukumar	January 23, 2026	Sell	89,100	4.75	423,400
January 27, 2026	Director	Nolan Sean P.	January 26, 2026	Sell	41,300	4.61	190,400
January 27, 2026	Executive	Alam Kamran	January 23, 2026	Sell	79,000	4.75	375,100
January 27, 2026	Director	Nagendran Sukumar	January 26, 2026	Sell	26,900	4.61	124,100
January 14, 2026	Director	Nagendran Sukumar	January 12, 2026	Sell	200,000	4.71	942,000
January 14, 2026	Director	Nagendran Sukumar	January 12, 2026	Buy	88,700	1.71	151,600
January 14, 2026	Director	Nagendran Sukumar	January 12, 2026	Buy	111,300	0.70	77,800

[Company Information]

Taysha Gene Therapies, Inc. was originally incorporated under Texas law on September 20, 2019. The company converted to a Delaware corporation on February 13, 2020. It is a patient-centric gene therapy company dedicated to developing and commercializing AAV-based gene therapies for the treatment of rare and large patient populations with central nervous system monogenic diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.